Open AccessAntipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients
Author(s) -
Nobutaka Ayani,
Takeshi Morimoto,
Mio Sakuma,
Toshiaki Kikuchi,
Koichiro Watanabe,
Jin Narumoto
Publication year - 2021
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001416
Subject(s) - polypharmacy , medicine , antipsychotic , risperidone , hazard ratio , confidence interval , retrospective cohort study , medical prescription , psychiatry , adverse effect , risk factor , schizophrenia (object oriented programming) , pharmacology
Antipsychotic (AP) polypharmacy (APP), the coprescription of more than 1 AP, is frequently practiced in psychiatric inpatients and is considered to be a risk factor for adverse drug events (ADEs). However, the association between APP and ADEs among psychiatric inpatients has not been well investigated.